CA3201690A1 - Multi-cyclic irak and flt3 inhibiting compounds and uses thereof - Google Patents
Multi-cyclic irak and flt3 inhibiting compounds and uses thereofInfo
- Publication number
- CA3201690A1 CA3201690A1 CA3201690A CA3201690A CA3201690A1 CA 3201690 A1 CA3201690 A1 CA 3201690A1 CA 3201690 A CA3201690 A CA 3201690A CA 3201690 A CA3201690 A CA 3201690A CA 3201690 A1 CA3201690 A1 CA 3201690A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- compound
- alkyl
- cycloalkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125654P | 2020-12-15 | 2020-12-15 | |
| US63/125,654 | 2020-12-15 | ||
| PCT/US2021/063567 WO2022132936A1 (en) | 2020-12-15 | 2021-12-15 | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3201690A1 true CA3201690A1 (en) | 2022-06-23 |
Family
ID=82058056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201690A Pending CA3201690A1 (en) | 2020-12-15 | 2021-12-15 | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12534469B2 (https=) |
| EP (1) | EP4262802A4 (https=) |
| JP (1) | JP2024500378A (https=) |
| CN (1) | CN116887834A (https=) |
| AU (1) | AU2021403015A1 (https=) |
| CA (1) | CA3201690A1 (https=) |
| IL (1) | IL303709A (https=) |
| MX (1) | MX2023006937A (https=) |
| WO (1) | WO2022132936A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| JP2025525322A (ja) * | 2022-06-15 | 2025-08-05 | チルドレンズ ホスピタル メディカル センター | 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用 |
| AU2024264188A1 (en) * | 2023-04-28 | 2025-11-06 | Kurome Therapeutics, Inc. | Irak inhibitor free base, salts, and polymorphic forms thereof |
| WO2025029929A1 (en) * | 2023-07-31 | 2025-02-06 | Children's Hospital Medical Center | Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof |
| WO2025137567A1 (en) * | 2023-12-20 | 2025-06-26 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101324804B1 (ko) * | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
| UY33304A (es) * | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| CA2806655A1 (en) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
| US10618903B2 (en) * | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| WO2017044623A1 (en) * | 2015-09-09 | 2017-03-16 | Lau Warren C | Methods, compositions, and uses of novel fyn kinase inhibitors |
| US11542261B2 (en) * | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| SG11202005237SA (en) * | 2017-12-15 | 2020-07-29 | Pyramid Biosciences Inc | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
| CN110835334B (zh) * | 2018-08-16 | 2022-10-18 | 中国药科大学 | 吲哚取代唑类化合物及其用途 |
-
2021
- 2021-12-15 EP EP21907719.5A patent/EP4262802A4/en active Pending
- 2021-12-15 WO PCT/US2021/063567 patent/WO2022132936A1/en not_active Ceased
- 2021-12-15 CN CN202180093259.3A patent/CN116887834A/zh active Pending
- 2021-12-15 MX MX2023006937A patent/MX2023006937A/es unknown
- 2021-12-15 JP JP2023535992A patent/JP2024500378A/ja active Pending
- 2021-12-15 CA CA3201690A patent/CA3201690A1/en active Pending
- 2021-12-15 US US18/257,746 patent/US12534469B2/en active Active
- 2021-12-15 IL IL303709A patent/IL303709A/en unknown
- 2021-12-15 AU AU2021403015A patent/AU2021403015A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024500378A (ja) | 2024-01-09 |
| CN116887834A (zh) | 2023-10-13 |
| US20240124468A1 (en) | 2024-04-18 |
| EP4262802A1 (en) | 2023-10-25 |
| EP4262802A4 (en) | 2024-11-13 |
| WO2022132936A1 (en) | 2022-06-23 |
| AU2021403015A1 (en) | 2023-08-03 |
| US12534469B2 (en) | 2026-01-27 |
| MX2023006937A (es) | 2023-10-13 |
| IL303709A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3201690A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| US12071425B2 (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
| JP2023538242A (ja) | 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 | |
| WO2023059582A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| CA3226908A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| US20250368648A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| US12612410B2 (en) | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | |
| WO2023150601A2 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| EP4598539A2 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| WO2023250431A9 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| KR20260004307A (ko) | 다환성 irak 및 flt3 억제 화합물 및 이의 용도 | |
| WO2025137567A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| HK40101779A (zh) | 多环irak和flt3抑制化合物以及其用途 | |
| CN118613480A (zh) | 多环irak和flt3抑制化合物以及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260205 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260205 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260210 |